CZMWY.US Carl Zeiss Meditec AG ADR
- Market cap
- USD 3.39B
- P/E
- 23.9x
- P/B
- 1.41x
- ROE
- 4.1%
- Dividend yield
- 1.62%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is CZMWY.US undervalued?
Graham numberCZMWY.US trades 22.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Carl Zeiss Meditec AG ADR fundamental analysis
No fundamental analysis for Carl Zeiss Meditec AG ADR yet.
Carl Zeiss Meditec AG ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Carl Zeiss Meditec AG ADR
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical o…
Full company profileCarl Zeiss Meditec AG ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Carl Zeiss Meditec AG ADR annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.09B | 1.19B | 1.28B | 1.46B | 1.34B | 1.65B | 1.90B | 2.09B | 2.07B | 2.23B | 2.71B |
| Gross Profit | 580M | 657M | 710M | 832M | 746M | 967M | 1.13B | 1.21B | 1.09B | 1.18B | 1.37B |
| Operating Income | 154M | 172M | 197M | 253M | 159M | 351M | 372M | 327M | 121M | 223M | 131M |
| EBITDA | 166M | 215M | 213M | 312M | 267M | 410M | 483M | 502M | 320M | 347M | 270M |
| Net Income | 98.3M | 134M | 126M | 160M | 122M | 236M | 294M | 290M | 179M | 141M | 86.7M |
| EPS | 1.21 | 1.57 | 1.41 | 1.79 | 1.37 | 2.64 | 3.29 | 3.25 | 2.01 | 1.61 | 1.00 |
| Balance Sheet | |||||||||||
| Total Assets | 1.25B | 1.62B | 1.66B | 2.02B | 2.01B | 2.40B | 2.82B | 3.03B | 3.39B | 4.06B | - |
| Total Liabilities | 397M | 381M | 347M | 605M | 563M | 719M | 793M | 860M | 1.34B | 1.56B | -2.11B |
| Shareholders' Equity | 798M | 1.22B | 1.29B | 1.40B | 1.43B | 1.66B | 2.02B | 2.16B | 2.04B | 2.49B | 2.11B |
| Cash & Short-term Investments | 8.71M | 8.32M | 7.84M | 22.6M | 5.20M | 7.44M | 7.73M | 10.6M | 20.3M | 27.3M | 23.9M |
| Total Debt | 8.98M | 5.81M | 10.9M | 57.5M | 68.6M | 121M | 128M | 156M | 154M | 132M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 112M | 37.7M | 187M | 220M | 179M | 363M | 188M | 251M | 247M | 232M | - |
| Capital Expenditure | 27.9M | 39.0M | 34.8M | 46.7M | 45.0M | 66.1M | 82.0M | 114M | 152M | 43.5M | 13.6M |
| Free Cash Flow | 83.9M | -1.29M | 152M | 173M | 134M | 297M | 106M | 137M | 95.1M | 188M | - |
| Ratios | |||||||||||
| ROE | 12.3% | 11.1% | 9.8% | 11.4% | 8.5% | 14.2% | 14.6% | 13.4% | 8.8% | 5.7% | 4.1% |
| ROA | 7.9% | 8.3% | 7.6% | 7.9% | 6.1% | 9.9% | 10.4% | 9.6% | 5.3% | 3.5% | - |
| Net Profit Margin | 9.0% | 11.3% | 9.9% | 10.9% | 9.2% | 14.3% | 15.4% | 13.9% | 8.7% | 6.3% | 3.2% |
| Debt to Equity | 0.01x | 0.00x | 0.01x | 0.04x | 0.05x | 0.07x | 0.06x | 0.07x | 0.08x | 0.05x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Carl Zeiss Meditec AG ADR dividends
- Dividend yield
- 1.62%
- Forward dividend
- 0.63 USD
- Payout ratio
- 41.1%
- Ex-dividend date
- Mar 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 58.0M | 0.66 | 41.1% |
| 2024 | EUR 98.2M | 1.11 | 54.9% |
| 2023 | EUR 98.4M | 1.10 | 33.9% |
| 2022 | EUR 80.5M | 0.90 | 27.4% |
| 2021 | EUR 44.7M | 0.50 | 18.9% |
| 2020 | EUR 58.1M | 0.65 | 47.5% |
| 2019 | EUR 49.2M | 0.55 | 30.8% |
| 2018 | EUR 49.2M | 0.55 | 38.9% |
| 2017 | EUR 37.6M | 0.44 | 27.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Carl Zeiss Meditec AG ADR
Ownership data of Carl Zeiss Meditec AG ADR is not available yet.
Carl Zeiss Meditec AG ADR company profile
- Company name
- Carl Zeiss Meditec AG ADR
- Ticker
- CZMWY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,784
- Fiscal year end
- September
- Address
- Göschwitzer Straße 51-52, Jena, Germany, 07745
- Phone
- 49 3641 220 115
About Carl Zeiss Meditec AG ADR
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
Carl Zeiss Meditec AG ADR management
10- Mr. Justus Felix WehmerCFO & Member of the Management Board · born 1965
- Dr. Christian MunsterHead of Global Regulatory & Clinical Affairs, CoCe Site Jena & Emp. Rep. Member of Supervisory Board · born 1971
- Mr. Andreas PecherInterim Chairman of the Management Board & Interim CEO · born 1971
- Stefanie SpanagelChief Operating Officer
- Mr. Sebastian FrericksDirector of Investor Relations
- Eva-Maria HeineChief Human Resources Officer
- Mr. Steven C. Schallhorn M.D.Chief Medical Officer for Global Ophthalmic Devices
- Mr. Andrew ChangHead of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec, Inc.
- Dr. Euan S. Thomson Ph.D.President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit · born 1963
- Mr. Magnus ReibenspiessHead of the Microsurgery Strategic Business Unit - ZEISS Medical Technology